Last Updated: 16 February 2025
In healthcare, AI is no longer just a promise—it’s a reality that is transforming the industry every day. It is improving how doctors diagnose diseases, manage treatments, and deliver patient care. And this is only the start: multiple studies show that we're only at the beginning of AI’s role in healthcare.
For example, a recent study from Forrester also suggests that 46% of U.S. healthcare organizations are already in the early stages of implementing generative AI into their production processes. Meanwhile, Tebra claims that although only 10% of healthcare professionals in the U.S. currently integrate AI into their practices, nearly half plan to do so in the near future.
These studies make one thing clear: we are still in the very early stages of AI adoption in the industry, and healthcare AI companies are playing a key role in its expansion.
From AI-driven telehealth making care more accessible to advanced medical imaging improving diagnostic accuracy, different industry trends are driving this change. Natural language processing (NLP) is easing administrative workloads, giving doctors more time to focus on patients. At the same time, predictive analytics is helping healthcare providers identify risks early and refine treatment plans for better outcomes.
The world expects more uses of AI in healthcare in the future, with technologies such as digital twins, AI-driven robotics in surgery, and real-time data processing from wearable devices set to push personalized medicine and public health to new levels.
To rank the top AI healthcare companies and startups, at Just AI News we decided to evaluate different key factors such as financial backing and the level of innovation, but also the tangible real-world impact. We looked at how well these companies are positioned to not only attract investment but also drive meaningful change in the industry-especially focusing on those that are innovating in AI.
Tempus AI is a health technology company focused on using artificial intelligence to advance precision medicine. Founded in 2015 by Eric Lefkofsky in Chicago, following his personal experience with cancer care, Tempus aims to improve patient outcomes by leveraging large sets of clinical and molecular data.
The company’s AI platform combines genomic information with clinical records to offer personalized treatment recommendations. This approach helps doctors make faster, data-driven decisions, initially in cancer care and now expanding into cardiology, neurology, and imaging services. By building one of the largest libraries of patient data, Tempus enables more tailored treatments and enhances overall care.
Unlike many traditional pharmaceutical or medtech companies that add AI features to existing products, Tempus was designed from the ground up with data science at its core. This focus allows the company to quickly adopt advanced methods like deep learning and AI-driven biomarker discovery, fostering rapid innovation in clinical solutions.
On June 14, 2024, Tempus went public on the Nasdaq under the ticker symbol "TEM."
Google Health is focused on improving global healthcare by integrating artificial intelligence into medical solutions. Its goal is to make health information more accessible and useful, supporting both individuals and healthcare providers.
The company has developed AI models like MedLM to help clinicians interpret complex medical data, such as lab results and imaging. It also launched Vertex AI Search for Healthcare, a tool that enables professionals to quickly locate and summarize key patient information, improving workflow efficiency. Additionally, Google Health’s AI-powered tuberculosis detection system analyzes chest X-rays to identify early signs of the disease, aiming to enhance diagnosis in regions with limited medical resources.
In late 2024, Verily, a subsidiary of Google Health, partnered with a major U.S. health system to apply AI in managing chronic diseases. The collaboration focuses on early disease detection and personalized treatment planning, reinforcing Verily’s role in AI-driven healthcare.
Medtronic is a global healthcare technology company focused on developing solutions that improve patient health. Founded in 1949, it provides a wide range of medical devices and therapies to address complex conditions. The company’s mission is to alleviate pain, restore health, and extend life for patients around the world.
The company is at the forefront of integrating AI into healthcare. One notable innovation is the GI Genius™ intelligent endoscopy module, an AI-assisted colonoscopy tool that helps physicians detect polyps that can lead to colorectal cancer.
Developed in collaboration with Cosmo Pharmaceuticals, GI Genius™ uses advanced AI algorithms to analyze colonoscopy images in real-time, enhancing the accuracy of polyp detection and improving patient outcomes.
ResMed is a global company specializing in digital health technologies and cloud-connected medical devices, serving patients in more than 140 countries. It focuses on helping individuals with sleep apnea, COPD, and other chronic respiratory conditions breathe more easily and improve their quality of life. With a focus on innovation, ResMed designs personalized healthcare solutions that integrate seamlessly into daily routines.
The company leverages artificial intelligence to analyze data from its connected devices, turning it into actionable insights for both patients and clinicians. Its AirSense machines, for example, use AI-powered algorithms to adjust therapy breath by breath, while the Dawn app functions as a virtual sleep health assistant.
By monitoring usage patterns, tracking progress, and providing tailored feedback, ResMed’s AI tools help deliver more precise and timely interventions, enhancing respiratory care.
Hims & Hers is a telehealth company focused on making personalized healthcare more accessible. Serving over 1.5 million customers, it connects individuals with licensed medical providers, offering both well-established treatments and innovative solutions. The platform prioritizes convenience, integrating online consultations and medication delivery to improve both physical and mental well-being.
One of its key advancements is MedMatch, a generative AI tool designed to analyze anonymized patient data and help providers recommend more precise treatments, starting with mental health care. By combining large-scale data analysis with clinical expertise, Hims & Hers aims to streamline care, improve patient outcomes, and support clinicians with evidence-based recommendations that reduce uncertainty in treatment plans.
Hims & Hers stands out for its seamless integration of AI into its core telehealth services, backed by strong financial investment and growing adoption. Its focus on data-driven personalization has improved treatment accuracy and user engagement across an expanding customer base.
Recursion is a biotechnology company using AI and automation to transform drug discovery. With a mission to decode biology and radically improve lives, the company applies machine learning to vast datasets to accelerate the development of new medicines. By integrating AI-driven insights with biological and chemical data, Recursion aims to make drug discovery faster, more precise, and cost-effective.
Through its AI-powered platform, Recursion analyzes over 60 petabytes of biological and chemical data to predict drug interactions and uncover new therapies. The company’s 2024 merger with Exscientia strengthened its capabilities by combining AI-driven molecular design with Recursion’s biological exploration, further advancing its goal of developing first-in-class and best-in-class treatments.
In November 2024, Recursion completed its landmark merger with Exscientia, expanding its global presence and reinforcing its position as a leader in AI-driven drug discovery.
Stryker is a global leader in medical technology, dedicated to improving healthcare through AI-driven innovations in surgery, imaging, and patient care. With a strong presence in MedSurg, Neurotechnology, and Orthopaedics, the company enhances clinical decision-making, streamlines workflows, and supports caregivers with advanced solutions.
Stryker has invested $100 million in AI initiatives, integrating robotic-assisted surgery, predictive analytics, and AI-enhanced imaging to improve diagnostics and treatment. AI also powers inventory management and remote patient monitoring, ensuring better resource allocation and real-time patient insights for proactive care.
In September 2024, Stryker acquired Care.ai, strengthening its healthcare IT and smart hospital solutions. This move expands its AI-powered ecosystem, creating more efficient and connected care environments for hospitals and patients.
Eli Lilly is a long-established pharmaceutical innovator with a heritage dating back over 145 years, founded by Colonel Eli Lilly on principles of integrity, excellence, and respect for people. Today, its research spans key therapeutic areas such as diabetes, obesity, Alzheimer’s disease, cancer, and immunology, all in pursuit of its guiding purpose: to create medicines that make life better for people around the world.
As part of its forward-thinking strategy, Lilly is integrating artificial intelligence into various stages of drug discovery and clinical development.
By collaborating with AI-focused research partners, Lilly accelerates the identification of new molecular targets, enhances the design of clinical trials, and refines data analysis.
We’ve included Eli Lilly in our top rankings for its innovative melding of deep-rooted pharmaceutical expertise with modern AI research—demonstrating how a traditional industry leader can leverage cutting-edge technology to push medical frontiers and continuously improve patient outcomes.
Merck is a global biopharmaceutical company dedicated to developing life-saving medicines and vaccines. With over 130 years of experience, Merck focuses on research-driven innovation to prevent and treat diseases in both humans and animals. The company’s mission is to advance healthcare through cutting-edge science, improving lives worldwide.
Merck is leveraging AI and high-throughput screening to accelerate drug discovery and development. By integrating machine learning into its research and clinical trials, the company enhances efficiency, reduces costs, and increases the speed at which new treatments reach patients.
AI also supports personalized medicine, allowing for more targeted and effective therapies.
Gilead Sciences is a research-based biopharmaceutical company dedicated to developing innovative medicines for serious diseases. With a strong foundation in HIV/AIDS, liver diseases, and oncology, Gilead is expanding its focus through cutting-edge science and strategic partnerships. The company is committed to improving global health by delivering breakthrough therapies and reducing barriers to care.
Gilead is leveraging AI-driven drug discovery through a strategic collaboration with Genesis Therapeutics. This partnership utilizes GEMS (Genesis Exploration of Molecular Space), an advanced AI platform that combines machine learning, language models, and molecular simulations to accelerate the design of small molecule therapies. By targeting complex diseases with limited treatment options, Gilead aims to speed up drug development and bring life-saving medicines to patients faster.
In 2024, Gilead invested $35 million upfront in its partnership with Genesis Therapeutics, focusing on AI-powered preclinical drug research.
Abbott Laboratories is a global healthcare company that develops medical devices, diagnostics, nutritional products, and pharmaceuticals. Known for innovations like the FreeStyle Libre glucose monitoring system, Abbott integrates artificial intelligence (AI) into its technologies to enhance diagnostics and patient care.
The company uses AI to analyze large datasets, improving diagnostic accuracy and enabling personalized treatments.
In collaboration with iCardio.ai, Abbott is incorporating AI into its imaging systems, particularly for electrophysiology, to assist in diagnosing and treating cardiac arrhythmias like atrial fibrillation.
These advancements help clinicians visualize conditions more effectively and automate model creation for better patient outcomes.
Boston Scientific is a medical device company specializing in technologies for cardiology, urology, neurology, and other interventional specialties.
The company incorporates artificial intelligence (AI) to improve procedural efficiency, patient monitoring, and treatment outcomes. AI-powered tools like BeatLogic and the LUX-Dx Insertable Cardiac Monitor provide real-time insights to support the diagnosis and management of cardiac conditions.
Additionally, Boston Scientific uses AI-driven imaging analysis to enhance decision-making during minimally invasive procedures and applies predictive analytics to optimize device performance.
Biogen is a biotechnology company focused on developing therapies for neurological diseases such as Alzheimer’s and multiple sclerosis.
The company leverages artificial intelligence (AI) to accelerate drug discovery, improve clinical trial efficiency, and enhance disease monitoring. Machine learning algorithms analyze complex biological data to identify potential therapeutic targets, while AI-driven digital health tools track disease progression in real time, enabling more personalized treatment approaches.
By integrating AI into its research and development processes, Biogen aims to advance neuroscience and improve care for patients with debilitating neurological conditions.
Lunit is a South Korean medical AI company focused on improving cancer detection and treatment through advanced deep learning technology. Its AI-powered INSIGHT suite analyzes X-rays and mammograms to detect early-stage cancers with high accuracy, while the SCOPE platform provides AI biomarkers to predict patient responses to immunotherapy, supporting personalized cancer care.
Lunit’s technology is used in over thousands healthcare institutions worldwide, and its recent acquisition of Volpara Health Technologies strengthens its breast health screening capabilities.
By integrating AI with real-world clinical applications, Lunit helps healthcare providers diagnose cancer earlier and tailor treatments more effectively.
Viz.ai develops AI-powered tools that assist clinicians in identifying and managing time-sensitive medical conditions like strokes and pulmonary embolisms. Its platform analyzes medical imaging in real time and alerts healthcare teams to critical findings, reducing treatment delays and improving coordination.
Designed to integrate smoothly into hospital workflows, Viz.ai's technology is FDA-cleared and widely used in hospitals to support faster, data-driven decisions in emergency care.
By applying AI to automate detection and streamline communication, Viz.ai helps medical teams respond more efficiently to life-threatening conditions.
Butterfly Network develops portable ultrasound technology that makes medical imaging more accessible. Its Butterfly iQ+ device replaces multiple traditional transducers with a single silicon chip, allowing clinicians to perform whole-body ultrasound scans using a smartphone.
AI assists users by identifying anatomical structures and optimizing imaging settings in real time, helping both specialists and general practitioners obtain clearer diagnostic images.
The company’s cloud-based platform enables secure storage and sharing of ultrasound data, enhancing collaboration and improving diagnostic accuracy across different healthcare environments.
Komodo Health applies AI and data analytics to map patient journeys and improve healthcare decision-making. Its Healthcare Map™ solution aggregates de-identified patient data to provide insights into disease progression, treatment effectiveness, and healthcare disparities.
By combining machine learning with real-world evidence, Komodo’s platform helps life sciences companies, payers, and providers make data-driven decisions to enhance patient care.
The company’s AI-powered analytics support efforts to optimize resource allocation, identify unmet medical needs, and improve health outcomes on a broader scale.
Freenome is a biotechnology company using AI and multiomics technology to detect cancer through non-invasive blood tests. Its platform analyzes genomic, proteomic, and epigenomic data with machine learning to identify cancer-related biomarkers at early stages.
This approach enables personalized screening strategies based on individual risk factors while improving the accuracy of cancer diagnostics.
Freenome collaborates with healthcare providers to integrate its AI-driven solutions into clinical practice, aiming to make early cancer detection more accessible and improve treatment outcomes through earlier interventions.
Biofourmis is a healthcare technology company that uses artificial intelligence to monitor patients remotely and personalize treatment plans. Its platform analyzes over 120 biomarkers in real time, detecting early signs of health deterioration and enabling timely interventions. This approach helps reduce hospital readmissions and supports the management of chronic conditions.
In 2024, Biofourmis merged with CopilotIQ to expand its AI-driven in-home care capabilities, covering everything from pre-surgical optimization to chronic disease management.
By integrating AI with clinical workflows, Biofourmis enhances patient care and improves healthcare efficiency.
HeartFlow specializes in AI-powered cardiovascular diagnostics, providing a non-invasive way to assess coronary artery disease. Its technology converts standard CT scans into detailed 3D models of a patient’s coronary arteries, allowing physicians to evaluate blockages and blood flow without invasive procedures.
This AI-driven analysis helps doctors make informed treatment decisions, improving accuracy and reducing unnecessary interventions.
HeartFlow’s approach enhances cardiovascular care by offering a safer, more efficient alternative to traditional diagnostic methods.
Qure.ai is an AI-driven healthcare company transforming medical imaging through deep learning technology. Founded in 2016 and based in Mumbai, India, Qure.ai aims to make healthcare more accessible and equitable by improving the speed and accuracy of radiology interpretations. Their AI-powered tools assist medical professionals in diagnosing conditions like tuberculosis, lung cancer, and stroke, helping patients receive faster and more accurate care.
Qure's AI solutions analyze X-rays, CT scans, and ultrasounds in real time, enabling healthcare providers to detect diseases earlier and improve patient outcomes. Their technology is deployed in over 2,700 imaging sites across 90+ countries, supporting radiologists with faster and more efficient diagnoses. The company also offers a care coordination suite, which streamlines patient triage and ensures real-time clinical communication, reducing delays in treatment.
In its latest Series D funding round, Qure.ai secured $65 million, reinforcing its position as one of the most widely adopted healthcare AI solutions.
Owkin is a biotech company that applies AI to accelerate drug discovery and improve medical research. Using federated learning, its AI models analyze patient data across multiple institutions without compromising privacy. This enables researchers to identify disease patterns, predict treatment responses, and develop more targeted therapies.
Owkin collaborates with pharmaceutical companies and healthcare institutions to enhance oncology research and support precision medicine initiatives. Its AI-driven approach helps streamline drug development and improve patient outcomes.
K Health is a digital health company offering AI-powered primary care through its mobile app. Its chatbot analyzes users’ symptoms against a large database of real-world medical cases to provide immediate health insights. Users can also connect with licensed doctors for further evaluation. By automating symptom analysis and streamlining access to care, K Health makes healthcare more affordable and accessible.
The company partners with organizations like the Mayo Clinic to refine its AI models and expand its medical knowledge base.
Insilico Medicine is a biotechnology company that applies artificial intelligence to accelerate drug discovery and development. Its Pharma.AI platform uses generative AI and deep learning to identify new therapeutic targets and design drug candidates, significantly reducing the time and cost of traditional research methods.
The company integrates AI across biology, chemistry, and clinical development to streamline the entire drug discovery process. Insilico has already advanced AI-designed drugs into clinical trials, including a treatment for idiopathic pulmonary fibrosis.
By combining automation with data-driven insights, the company focuses on developing therapies for conditions such as cancer, fibrosis, and age-related diseases.
Aidoc develops AI-powered radiology solutions that help healthcare providers detect and prioritize critical conditions. Its deep learning algorithms analyze medical images in real time, flagging urgent cases such as strokes, pulmonary embolisms, and brain hemorrhages.
By integrating seamlessly into hospital workflows, Aidoc enables radiologists to diagnose conditions faster and improve patient care in emergency settings.
The platform is FDA-cleared and widely used in hospitals and imaging centers worldwide, assisting healthcare teams in making timely, data-driven decisions.
SOPHiA GENETICS is a health technology company that uses artificial intelligence to analyze genomic and clinical data, helping doctors diagnose and treat diseases more effectively. Its SOPHiA DDM™ platform applies machine learning to identify genetic variants linked to cancer and rare diseases, providing insights that support personalized treatment plans.
By integrating multimodal data, the company enables healthcare providers to make more informed decisions while improving access to precision medicine.
SOPHiA GENETICS collaborates with hospitals and research institutions worldwide to advance data-driven healthcare.
We crafted this ranking of top medical and healthcare AI companies by looking at a mix of factors, including company size, funding, market influence, innovation, scalability, and how they stand out in a competitive field.
One of the biggest considerations was how each company uses AI to drive healthcare forward—whether by improving diagnostics, streamlining drug discovery, or enhancing patient care. While some of these companies are large, established players and others are fast-growing innovators, they’re all making a significant impact in the industry.
Since healthcare and AI are evolving rapidly, we’ll keep this list updated with the latest breakthroughs and emerging companies shaping the future of the field.
We do our best to keep our rankings accurate and up to date. If you think your company should be added—or if you have updates or additional details to share—contact us. We’re always happy to hear from industry leaders driving innovation in healthcare.
